is compounded semaglutide approved by the fda Warns on Certain Forms of The End of Compounded Semaglutide:

The combination has not been formally studied in large clinical trials and is not approved by the FDA as a standard treatment

Retatrutide + MOTS-c Storage & Handling Storage Reference (Both Compounds) State Lyophilized (long-term) Retatrutide -4 F (-20 C), 12+ months MOTS-c -4 F (-20 C), 12+ months State Lyophilized (short-term) Retatrutide 35.6-46.4 F (2-8 C), several months MOTS-c 35.6-46.4 F (2-8 C), several months State Lyophilized (room temp) Retatrutide Weeks (shipping tolerance only) MOTS-c Weeks (shipping tolerance only) State Reconstituted (liquid) Retatrutide 35.6-46.4 F (2-8 C), up to 28-60 days MOTS-c 35.6-46.4 F (2-8 C), up to 7 days State Aliquot frozen reconstituted Retatrutide Not standard practice MOTS-c -4 F (-20 C), 2-3 months State Color when reconstituted Retatrutide Clear MOTS-c Clear State Light protection Retatrutide Yes MOTS-c Yes State Oral viable Retatrutide No MOTS-c No MOTS-c's 7-day reconstituted window is the limiting factor for storage planning

In some embodiments, administration of the semaglutide and cagrilintide pharmaceutical formulations disclosed herein results in a higher HbAi c reduction, in Copoints, compared to that which results from treatment with either semaglutide as sole active ingredient or cagrilintide as sole active ingredient

Skipping days or using it sporadically could reduce its effectiveness

"Robert Kennedy, Jr.'s Biography"